



Better Health, Brighter Future

**Redemption of \$900,000,000 2.400% Senior Notes due 2021**

CUSIP/ISIN No. 82481L AB5 / US82481LAB53

Notice is hereby given that Shire Acquisitions Investments Ireland DAC ("SAIIDAC"), an indirect wholly-owned subsidiary of Takeda Pharmaceutical Company Limited ("Takeda"), redeemed \$900,000,000 outstanding aggregate principal amount of the 2.400% Senior Notes due 2021 (the "2021 Notes") on January 22, 2021 (the "Redemption"). Accordingly, the entire 2021 Notes have been cancelled and there are no 2021 Notes outstanding.

The 2021 Notes were issued pursuant to an Indenture (the "Base Indenture") dated as of September 23, 2016, by and between SAIIDAC and Deutsche Bank Trust Company Americas, as trustee (the "Trustee"), as supplemented and amended by the First Supplemental Indenture dated as of September 23, 2016 (the "First Supplemental Indenture"), the Second Supplemental Indenture dated as of December 1, 2016, the Third Supplemental Indenture dated as of February 4, 2019 and the Fourth Supplemental Indenture dated as of July 2, 2019 (collectively, the "Indenture"). The Redemption was made at the option of SAIIDAC and Takeda pursuant to Article 3 of the Base Indenture, Section 3.01 of the First Supplemental Indenture and the terms of the 2021 Notes established pursuant to Section 4.01 of the First Supplemental Indenture. On January 22, 2021, the 2021 Notes redeemed became due and payable at the redemption price applicable thereto as set forth in the Indenture and have ceased to bear interest.

January 22, 2021